1,733 research outputs found
An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer
BACKGROUND: The most common application of microarray technology in disease research is to identify genes differentially expressed in disease versus normal tissues. However, it is known that, in complex diseases, phenotypes are determined not only by genes, but also by the underlying structure of genetic networks. Often, it is the interaction of many genes that causes phenotypic variations. RESULTS: In this work, using cancer as an example, we develop graph-based methods to integrate multiple microarray datasets to discover disease-related co-expression network modules. We propose an unsupervised method that take into account both co-expression dynamics and network topological information to simultaneously infer network modules and phenotype conditions in which they are activated or de-activated. Using our method, we have discovered network modules specific to cancer or subtypes of cancers. Many of these modules are consistent with or supported by their functional annotations or their previously known involvement in cancer. In particular, we identified a module that is predominately activated in breast cancer and is involved in tumor suppression. While individual components of this module have been suggested to be associated with tumor suppression, their coordinated function has never been elucidated. Here by adopting a network perspective, we have identified their interrelationships and, particularly, a hub gene PDGFRL that may play an important role in this tumor suppressor network. CONCLUSION: Using a network-based approach, our method provides new insights into the complex cellular mechanisms that characterize cancer and cancer subtypes. By incorporating co-expression dynamics information, our approach can not only extract more functionally homogeneous modules than those based solely on network topology, but also reveal pathway coordination beyond co-expression
Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures.
Cancer results from dysregulation of multiple steps of gene expression programs. We review how transcriptome profiling has been widely explored for cancer classification and biomarker discovery but resulted in limited clinical impact. Therefore, we discuss alternative and complementary omics approaches
Recommended from our members
Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences
Advances in the technologies and informatics used to generate and process large biological data sets (omics data) are promoting a critical shift in the study of biomedical sciences. While genomics, transcriptomics and proteinomics, coupled with bioinformatics and biostatistics, are gaining momentum, they are still, for the most part, assessed individually with distinct approaches generating monothematic rather than integrated knowledge. As other areas of biomedical sciences, including metabolomics, epigenomics and pharmacogenomics, are moving towards the omics scale, we are witnessing the rise of inter-disciplinary data integration strategies to support a better understanding of biological systems and eventually the development of successful precision medicine. This review cuts across the boundaries between genomics, transcriptomics and proteomics, summarizing how omics data are generated, analysed and shared, and provides an overview of the current strengths and weaknesses of this global approach. This work intends to target students and researchers seeking knowledge outside of their field of expertise and fosters a leap from the reductionist to the global-integrative analytical approach in research
Lung Cancer Genomic Signatures
Background:Lung cancer (LC) is the dominant cause of death by cancer in the world, being responsible for more than a million deaths annually. It is a highly lethal common tumor that is frequently diagnosed in advanced stages for which effective alternative therapeutics do not exist. In view of this, there is an urgent need to improve the diagnostic, prognostic, and therapeutic classification systems, currently based on clinicopathological criteria that do not adequately translate the enormous biologic complexity of this disease.Methods:The advent of the human genome sequencing project and the concurrent development of many genomic-based technologies have allowed scientists to explore the possibility of using expression profiles to identify homogenous tumor subtypes, new prognostic factors of human cancer, response to a particular treatment, etc. and thereby select the best possible therapies while decreasing the risk of toxicities for the patients. Therefore, it is becoming increasingly important to identify the complete catalog of genes that are altered in cancer and to discriminate tumors accurately on the basis of their genetic background.Results and Discussion:In this article, we present some of the works that has applied high-throughput technologies to LC research. In addition, we will give an overview of recent results in the field of LC genomics, with their effect on patient care, and discuss challenges and the potential future developments of this area
Integrative Network Biology: Graph Prototyping for Co-Expression Cancer Networks
Network-based analysis has been proven useful in biologically-oriented areas, e.g., to explore the dynamics and complexity of biological networks. Investigating a set of networks allows deriving general knowledge about the underlying topological and functional properties. The integrative analysis of networks typically combines networks from different studies that investigate the same or similar research questions. In order to perform an integrative analysis it is often necessary to compare the properties of matching edges across the data set. This identification of common edges is often burdensome and computational intensive. Here, we present an approach that is different from inferring a new network based on common features. Instead, we select one network as a graph prototype, which then represents a set of comparable network objects, as it has the least average distance to all other networks in the same set. We demonstrate the usefulness of the graph prototyping approach on a set of prostate cancer networks and a set of corresponding benign networks. We further show that the distances within the cancer group and the benign group are statistically different depending on the utilized distance measure
Translational Oncogenomics and Human Cancer Interactome Networks
An overview of translational, human oncogenomics, transcriptomics and cancer interactomic networks is presented together with basic concepts and potential, new applications to Oncology and Integrative Cancer Biology. Novel translational oncogenomics research is rapidly expanding through the application of advanced technology, research findings and computational tools/models to both pharmaceutical and clinical problems. A self-contained presentation is adopted that covers both fundamental concepts and the most recent biomedical, as well as clinical, applications. Sample analyses in recent clinical studies have shown that gene expression data can be employed to distinguish between tumor types as well as to predict outcomes. Potentially important applications of such results are individualized human cancer therapies or, in general, ‘personalized medicine’. Several cancer detection techniques are currently under development both in the direction of improved detection sensitivity and increased time resolution of cellular events, with the limits of single molecule detection and picosecond time resolution already reached. The urgency for the complete mapping of a human cancer interactome with the help of such novel, high-efficiency / low-cost and ultra-sensitive techniques is also pointed out
Recommended from our members
Computational solutions for omics data
High-throughput experimental technologies are generating increasingly massive and complex genomic data sets. The sheer enormity and heterogeneity of these data threaten to make the arising problems computationally infeasible. Fortunately, powerful algorithmic techniques lead to software that can answer important biomedical questions in practice. In this Review, we sample the algorithmic landscape, focusing on state-of-the-art techniques, the understanding of which will aid the bench biologist in analysing omics data. We spotlight specific examples that have facilitated and enriched analyses of sequence, transcriptomic and network data sets.National Institutes of Health (U.S.) (Grant GM081871
MACHINE LEARNING APPROACHES FOR BIOMARKER IDENTIFICATION AND SUBGROUP DISCOVERY FOR POST-TRAUMATIC STRESS DISORDER
Post-traumatic stress disorder (PTSD) is a psychiatric disorder caused by environmental and genetic factors resulting from alterations in genetic variation, epigenetic changes and neuroimaging characteristics. There is a pressing need to identify reliable molecular and physiological biomarkers for accurate diagnosis, prognosis, and treatment, as well to deepen the understanding of PTSD pathophysiology. Machine learning methods are widely used to infer patterns from biological data, identify biomarkers, and make predictions. The objective of this research is to apply machine learning methods for the accurate classification of human diseases from genome-scale datasets, focusing primarily on PTSD.The DoD-funded Systems Biology of PTSD Consortium has recruited combat veterans with and without PTSD for measurement of molecular and physiological data from blood or urine samples with the goal of identifying accurate and specific PTSD biomarkers. As a member of the Consortium with access to these PTSD multiple omics datasets, we first completed a project titled Clinical Subgroup-Specific PTSD Classification and Biomarker Discovery. We applied machine learning approaches to these data to build classification models consisting of molecular and clinical features to predict PTSD status. We also identified candidate biomarkers for diagnosis, which improves our understanding of PTSD pathogenesis. In a second project, entitled Multi-Omic PTSD Subgroup Identification and Clinical Characterization, we applied methods for integrating multiple omics datasets to investigate the complex, multivariate nature of the biological systems underlying PTSD. We identified an optimal 2 PTSD subgroups using two different machine learning approaches from 82 PTSD positive samples, and we found that the subgroups exhibited different remitting behavior as inferred from subjects recalled at a later time point. The results from our association, differential expression, and classification analyses demonstrated the distinct clinical and molecular features characterizing these subgroups.Taken together, our work has advanced our understanding of PTSD biomarkers and subgroups through the use of machine learning approaches. Results from our work should strongly contribute to the precise diagnosis and eventual treatment of PTSD, as well as other diseases. Future work will involve continuing to leverage these results to enable precision medicine for PTSD
- …